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ABSTRACT
Colorectal cancer (CRC) develops through a multistep process and is modulated by inﬂammation.
However, the inﬂammatory pathways that support intestinal tumors at different stages remain
incompletely understood. Interleukin (IL)-33 signaling plays a role in intestinal inﬂammation, yet its
contribution to the pathogenesis of CRC is unknown.
Using immunohistochemistry on 713 resected human CRC specimens, we show here that IL-33 and its
receptor ST2 are expressed in low-grade and early-stage human CRCs, and to a lesser extent in higher-
grade and more advanced-stage tumors. In a mouse model of CRC, ST2-deﬁciency protects from tumor
development. Moreover, bone marrow (BM) chimera studies indicate that engagement of the IL-33/ST2
pathway on both the radio-resistant and radio-sensitive compartment is essential for CRC development.
Mechanistically, activation of IL-33/ST2 signaling compromises the integrity of the intestinal barrier and
triggers the production of pro-tumorigenic IL-6 by immune cells.
Together, this data reveals a tumor-promoting role of IL-33/ST2 signaling in CRC.
Abbreviations: AOM, azoxymethane; BM, bone marrow; CLN, caudal lymph nodes; CRC, colorectal cancer; DSS,
dextran sodium sulfate; FFPE, formalin-ﬁxed parafﬁn-embedded; H&E, hematoxylin and eosin; IEC, intestinal
epithelial cell; IHC, immunohistochemistry; IL, interleukin; IBD, inﬂammatory bowel diseases; LPS, lipopolysaccha-
ride; TMA, tissue microarray; UICC, Union for International Cancer Control; WT, wild-type
KEYWORDS: Colorectal
cancer; IL-33; inﬂamma-
tion; mouse model; ST2;
tissue microarray; tumor
microenvironment
Introduction
Despite substantial improvements in treatment and prognosis
during the past decades, CRC remains one of the most com-
mon human malignancies with lethal outcome in a consider-
able number of cases.1 Various genetic alterations in key
cellular pathways that underlie colon tumorigenesis have been
identiﬁed.2,3 There is now compelling evidence that intestinal
tumorigenesis is greatly promoted by chronic inﬂammation
that follows such genetically-driven tumor-initiating events.4
For example, patients suffering from inﬂammatory bowel dis-
eases (IBD) have an increased risk to develop colorectal carci-
nomas.5,6 Several pro-inﬂammatory cytokines including TNFa
and IL-6 are critically involved in the pathogenesis of IBD.7
Similarly, serum IL-6 levels in CRC patients are associated with
advanced-stage cancer, and increased blood concentration of
IL-6 is an independent adverse prognostic marker of survival.8
In addition, immune inﬁltrates within colorectal tumors can
negatively or positively inﬂuence patient survival, potentially
due to their distinct secretion patterns of cytokines.9 Therefore,
it is critical to determine the impact of speciﬁc cytokines on
CRC development, progression and patient survival.
Recently, the cytokine IL-33 has been described to fulﬁll
important functions in the intestine, including regulation of
barrier permeability and healing10 as well as immunity against
helminth infection.11 IL-33 protein is constitutively expressed
mainly in the nucleus of endothelial cells, epithelial barrier tis-
sues and myoﬁbroblasts,12-14 where it is complexed with chro-
matin and may modulate gene expression.15 Upon tissue stress
or damage, IL-33 is released as an alarmin and binds to a heter-
odimeric receptor complex consisting of ST2 (IL-1RL1) and IL-
1 receptor accessory protein to promote inﬂammation. ST2 is
expressed on the surface of a variety of cells, including epithelial
cells, stromal cells and immune cells. A soluble isoform of ST2
(sST2) might either function as a decoy receptor or might
extend the half-life of circulating IL-33.12,16
Mucosal IL-33 is increased in patients with active ulcerative
colitis (UC),14,1618 where it is highly expressed in subepithelial
myoﬁbroblasts below UC lesions.14,19 Levels of IL-33 and sST2
are elevated in sera of UC and Crohn’s disease (CD) patients.16
While human studies have established a consistent association
between intestinal inﬂammation and expression of IL-33 or ST2
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in IBD patients, mouse models of IBD addressing the function of
the IL-33/ST2 pathway have shown a more complex picture.
Genetic ablation of IL-3320 or ST210 ameliorated clinical symp-
toms and intestinal inﬂammation in the early phase of dextran
sodium sulfate (DSS) colitis. At the same time, and in apparent
contrast, Il33¡/¡ mice displayed delayed resolution of DSS-
dependent tissue damage20 and administration of exogenous IL-
33 ameliorated chronic DSS colitis.21 Therefore, the IL-33/ST2
pathway may exert multiple functions in intestinal disorders.
Since IL-33 has a profound impact on inﬂammatory patholo-
gies of the intestine, and since inﬂammation drives increased
proliferation and reduced apoptosis in the intestinal epithelium,4
we sought to investigate the role of IL-33/ST2 signaling in intes-
tinal tumorigenesis. Analysis of two independent patient cohorts
using human tissue microarrays (TMAs) revealed strong expres-
sion of both IL-33 and ST2 in less advanced and low-grade (G1-
2) CRCs, suggesting a carcinogenic role of the IL-33/ST2 axis
predominantly in early-stage carcinogenesis. IL-33 was also con-
sistently expressed in colonic adenomas. Mechanistic investiga-
tions using the azoxymethane (AOM)/DSS model of CRC in
mice indicated that genetic blockade of the IL-33/ST2 pathway
signiﬁcantly prevents tumor formation. In addition, activation of
the IL-33/ST2 pathway induces leakiness of the intestinal barrier
and production of IL-6 by immune cells, both known CRC pro-
moting factors. In summary, our data provides strong evidence
for a critical functional involvement of IL-33/ST2 signaling in
intestinal tumorigenesis.
Results
IL-33 and ST2 are expressed in early-stage colorectal
tumors
IL-33 has been functionally implicated in inﬂammatory disor-
ders,12 while only few studies so far have reported a clear
contribution of IL-33 to cancers. To investigate a potential
association between IL-33 and cancers of different organs, we
screened a database with expression data from a variety of can-
cer cell lines. Among the different types of cancers, elevated
transcript levels of IL33 were measured in a greater proportion
of established cell lines originating from the large intestine
compared to cells from other organs (Fig. S1A). Moreover,
in silico analysis of a gene expression library from tissue
biopsies or resections from the large intestine revealed
increased IL33 transcript levels in primary tumor samples com-
pared with healthy samples (p < 0.01) (Fig. S1B). This data
raised the possibility of a speciﬁc involvement of IL-33 in CRC
pathogenesis.
To investigate a potential role of IL-33 during CRC develop-
ment and progression, we performed immunohistochemistry
(IHC) for IL-33 on two independent CRC cohorts with a total
of 713 patients sampled on TMAs. Only IL-33 staining on
intestinal epithelial cells (IECs) was taken into account for the
analysis. Endothelial cells were consistently found to show posi-
tive IL-33 staining and therefore served as an internal positive
control for IL-33 staining (Fig. 1A and Fig. S2A). Both CRC
cohorts were combined for statistical analysis. One of the
cohorts also included 11 patients suffering from two synchro-
nous colorectal carcinomas with different locations in the colon
or rectum. These patients were excluded from the statistical
analysis.
Compared with healthy mucosa where it was not detected,
IL-33 expression was detected in a signiﬁcant number of ade-
nomas and low-grade adenocarcinomas (G12; p D 0.0003)
(Fig. 1A and Fig. S2B). IL-33-expressing tumors were signiﬁ-
cantly associated with an early pT stage (pT12; p D 0.0199)
and showed a tendency to have earlier Union for International
Cancer Control (UICC) stages (p D 0.0723) (Table 1). In addi-
tion, IL-33 was expressed in a higher proportion of low-grade
than high-grade tumors (G3) (Table 1).
Figure 1. Representative picture of TMA cores showing healthy mucosa, low-grade and high-grade adenocarcinomas, respectively. Sections were stained for (A) IL-33 or
(B) ST2. Scale bars: overview: 100 mm; inlay 25 mm.
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One of the 11 patients with two synchronous carcinomas
was diagnosed with two tumors in the sigmoid colon. Interest-
ingly, one carcinoma was an early-stage tumor (pT1) and
strongly expressed IL-33 in all tumor cells, whereas the other
carcinoma had a higher tumor stage (pT3) and was completely
negative for IL-33. Similarly, ST2 was strongly expressed in this
patient’s pT1 tumor, but not in the synchronous pT3 tumor
(data not shown).
Next we studied ST2 expression on the TMAs by IHC. As
expected, ST2 expression was detected in endothelial cells,
myoﬁbroblasts and inﬁltrating immune cells (Fig. S2C and D).
Similar to IL-33, only ST2 expression in the intestinal epithe-
lium was counted in our analysis (Fig. 1B), and like IL-33, ST2
was expressed and associated with earlier UICC stages (p D
0.0074) and lower tumor grade (G12; p D 0.0028) (Table 2).
In addition, ST2-positive cancers showed less frequent vascular
invasion (p D 0.0467) or lymph node metastases (p D 0.0052).
ST2-negative cancers were mostly located in the right hemico-
lon, whereas ST2-positive tumors were more frequently located
on the left side, including rectum (p D 0.0102).
It is of note that IL-33 or ST2 expressions were not associ-
ated with overall patient survival. However, epithelial IL-33
and ST2 expression correlated with low-grade and early-stage
tumors (Table S1). This suggests that the IL-33/ST2 pathway is
functionally active in these tissues.
Taken together, we conclude that IL-33 is speciﬁcally upre-
gulated in CRC. IL-33/ST2-positive CRCs are signiﬁcantly
associated with an early tumor stage, and IL-33 and ST2 do not
determine patient survival. Hence, our data implies that the IL-
33/ST2 pathway is effectively engaged particularly in adenomas
and low-grade / early-stage tumors.
Ablation of IL-33/ST2 signaling prevents CRC
tumorigenesis
To address the role of IL-33/ST2 signaling for tumorigenesis
in vivo, we used a murine model of CRC and injected wild-
type (WT) and St2¡/¡ mice twice with the procarcinogen
AOM, followed by three rounds of DSS feeding. AOM-
induced tumors typically follow the adenoma-carcinoma
Table 1. Association of clinicopathological features and IL-33
IL-33 Freq. (%)
Low (5%) High (>5%)
Feature
n D 576;
80.8%
n D 137;
19.2%
p
value
Patient age (n D 713) Median (range) 75 (15100) 73 (3295) 0.2189
Gender (n D 713)
Male 323 (56.1) 62 (45.3) 0.0224
Female 253 (43.9) 75 (54.7)
Tumor location
(n D 703)
Left 225 (39.6) 50 (37.0) 0.7668
Rectum 47 (8.3) 10 (7.4)
Right 296 (52.1) 75 (55.6)
pT (n D 713)
pT12 87 (15.1) 32 (23.4) 0.0199
pT34 489 (84.9) 105 (76.6)
pN (n D 705)
pN0 304 (53.2) 79 (59.0) 0.2484
pN12 267 (46.8) 55 (41.0)
pM (n D 505)
pM0 347 (79.2) 49 (73.1) 0.2592
pM1 91 (20.8) 18 (26.9)
UICC Stage (n D 705)
I 61 (10.7) 25 (18.7) 0.0723
II 223 (39.1) 52 (38.8)
III 196 (34.3) 39 (29.1)
IV 91 (15.9) 18 (13.4)
Tumor grade (n D 707)
G12 414 (72.6) 120 (87.6) 0.0003
G3 156 (27.4) 17 (12.4)
Lymphatic invasion
(n D 406)
L0 302 (86.8) 53 (91.4) 0.328
L1 46 (13.2) 5 (8.6)
Venous invasion (n D 466)
V0 294 (75.0) 59 (79.7) 0.3839
V12 98 (25.0) 15 (20.3)
Adjuvant therapy
(n D 291)
None 173 (70.0) 31 (70.5) 0.9559
Treated 74 (30.0) 13 (29.6)
OS (n D 349)
Median (95%CI) 66 (39120) 61 (34n.e.) 0.6868
OS, overall survival; n.e., not evaluable.
Table 2. Association of clinicopathological features and ST2
ST2 Freq. (%)
Low (30%) High (>30%)
Feature
n D 253;
55.4%
n D 204;
44.6% P-value
Patient age (n D 457) Median
(range)
75 (29100) 76 (1598) 0.4422
Gender (n D 457)
Male 146 (57.7) 113 (55.4) 0.6195
Female 107 (42.3) 91 (44.6)
Tumor location (nD447)
Left 95 (38.2) 100 (50.5) 0.0102
Rectum 15 (6.0) 16 (8.1)
Right 139 (55.8) 82 (41.4)
pT (n D 457)
pT12 35 (13.8) 32 (15.7) 0.5967
pT34 218 (86.2) 172 (84.3)
pN (nD454)
pN0 128 (50.8) 129 (63.9) 0.0052
pN12 124 (49.2) 73 (36.1)
pM (n D 456)
pM0 217 (85.8) 173 (85.2) 0.8685
pM1 36 (14.2) 30 (14.8)
UICC Stage (n D 454)
I 23 (9.1) 29 (14.4) 0.0074
II 94 (37.3) 93 (46.0)
III 99 (39.3) 50 (24.8)
IV 36 (14.3) 30 (14.9)
Tumor grade (n D 452)
G12 175 (70.0) 166 (82.2) 0.0028
G3 75 (30.0) 36 (17.8)
Lymphatic invasion (n D 406)
L0 181 (85.4) 174 (89.7) 0.1902
L1 31 (14.6) 20 (10.3)
Venous invasion (n D 417)
V0 169 (77.2) 168 (84.9) 0.0467
V12 50 (22.8) 30 (15.1)
Adjuvant therapy (n D 291)
None 99 (67.4) 105 (72.9) 0.2994
Treated 48 (32.7) 39 (27.1)
Overall survival (%) (n D 272)
Median
(95%CI)
66 (34n.e.) 53 (42120) 0.5802
n.e., not evaluable.
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sequence of malignant transformation while recapitulating
several molecular alterations similar to human CRC
(reviewed in22,23). However, metastasis has not been
reported for C57BL/6 mice treated with AOM/DSS. There-
fore, the AOM/DSS model of experimental CRC is reﬂective
of the early-stage events leading to colorectal tumorigenesis
in patients. We found that St2¡/¡ mice were signiﬁcantly
protected from AOM/DSS-triggered CRC as they displayed
fewer tumors than WT counterparts (p D 0.0064) (Fig. 2A
and B). Tumor load was also lower in St2¡/¡ mice (p D
0.0019) (Fig. 2B). Furthermore, WT mice showed higher-
grade tumors (p D 0.0489) including some cases of invasive
carcinomas which were absent in St2¡/¡ animals (Fig. 2B
and C). This result was conﬁrmed by endoscopic analysis of
tumor-bearing mice over time, where large tumors became
detectable earlier in WT compared with St2¡/¡ mice
(Fig. S3).
Interestingly, transcript levels of Il33 and St2 progressively
increased over time in whole colon tissue of mice treated with
AOM/DSS (Fig. S4A and B, respectively).
As for biopsies of early-stage CRCs in patients, IL-33 pro-
tein expression was increased in mouse tumors in compari-
son to healthy and/or tumor-free tissue, and mainly
restricted to IECs (Fig. 3A and Fig. S4C). In addition, St2
was upregulated at the mRNA level in tumors versus adja-
cent tumor-free colons (Fig. 3B). Finally, we assessed the
expression of selected target genes in size-matched tumors of
WT and St2¡/¡ mice vs. adjacent, tumor-free colon. These
genes were either biomarkers for known biological functions
of IL-33 such as Mpo for neutrophil inﬂux,24 the macrophage
marker Arg1, or known IL-33 target genes that were reported
to be important for inﬂammation-driven tumorigenesis.2528
Transcription of chemokine genes Cxcl1, Cxcl2 and Ccl2 and
cytokine genes Il6, Tnf, Il11, Il1b and Il17a was increased in
tumors versus control tissue, yet independently of IL-33/ST2
signaling (Fig. S5AH). Similarly, there was no signiﬁcant
difference in the expression of Mpo, Nos2 and Arg1 (Fig. S5I
and K). Since there were no differences in the analyzed tran-
script levels between WT and St2¡/¡ tumors at a late time
point of our model (10 weeks post induction), these results
suggest that the observed tumorigenic effects are indepen-
dent of the above IL-33-dependent inﬂammatory target
genes and their mechanisms at the analyzed time point of
the AOM/DSS model.
Taken together, our data indicates that the IL-33/ST2 path-
way is preferentially upregulated in colonic tumors and con-
tributes to CRC development.
Pleiotropic function of IL-33/ST2 signaling in CRC
tumorigenesis
Next we generated sets of reciprocal BM chimeric mice to
assess the relative contribution of the radio-resistant/stroma vs.
the radio-sensitive/hematopoietic compartment to IL-33/ST2-
dependent CRC development. Overall, we observed fewer and
smaller tumors in chimeric mice, likely due to antibiotic treat-
ment during BM reconstitution, as reported by others.29 Yet we
found that chimeras with disrupted IL-33/ST2 signaling either
in the stroma or the hematopoietic system developed fewer
tumors and showed lower tumor load compared with control
Figure 2. Genetic disruption of the IL-33/ST2 axis protects mice from AOM/DSS-induced CRC. (A) Macroscopic pictures of colonic tumors in representative WT and St2¡/¡
mice. Black arrowheads indicate single tumors. (B) Reduction in number of tumors, tumor load and tumor grade in St2¡/¡ compared with WT mice. (C) Representative
hematoxylin and eosin (H&E) sections displaying the most advanced tumor grades in WT and St2¡/¡ groups. Scale bars: overview: 200 mm; inlay 50 mm. Data represent
means§ SEM; n D 9 samples per group. Statistical analyses were performed using Student t test (tumor number and severity) or MannWhitney test (tumor load).
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mice that were sufﬁcient for IL-33/ST2 signaling in both com-
partments (Fig. 4). Further, our results suggest that both
compartments contributed to tumor formation through an
ST2-dependent mechanism. Therefore, engagement of the
IL-33/ST2 pathway on both radio-resistant and hematopoietic
cells critically supports CRC development.
IL-33/ST2 signaling promotes epithelial leakiness and IL-6
production
Evidence from chimeric mice led us ﬁrst to assume a direct pro-
tumorigenic effect of the IL-33/ST2 pathway on radio-resistant
colonic epithelial cells. ST2 is expressed by several human colon
cancer cell lines (Fig. S6A). However, stimulation of ST2-
expressing HT-29, Caco-2 and LS 174T cells with IL-33 did not
modulate their proliferation rate (Fig. S6B, C and D), even
when cultured with reduced serum concentrations (data not
shown). These results argued against a direct role of IL-33 in
the regulation of IEC proliferation in CRC.
Therefore we analyzed whether IL-33 modulated other
parameters of the colonic epithelium. A recent study suggested
that IL-33 regulates intestinal permeability,10 and CRC tumori-
genesis is associated with a deterioration of the epithelial bar-
rier.30 To address how IL-33/ST2 signaling may affect intestinal
barrier function in inﬂammation-associated CRC, we generated
BM chimeric mice that expressed ST2 selectively on radio-resis-
tant cells and treated them with one cycle of DSS. Compared to
St2¡/¡-to-St2¡/¡ chimeric mice, we found in these chimeras an
increased translocation of bacteria from the intestine, as indi-
cated by presence of bacterial 16S rRNA in liver and higher
lipopolysaccharide (LPS) levels in sera (Fig. S7, Fig. 5A). This
demonstrated that IL-33/ST2 signaling on the radio-resistant
compartment during colonic inﬂammation compromises the
integrity of the intestinal barrier, a physiologic parameter sug-
gested to contribute to CRC.30
In line with increased serum LPS levels, we found elevated
IL-6 in the serum of DSS-treated St2¡/¡-to-WT chimeric mice
that have intact IL-33/ST2 signaling in their radio-resistant
compartment (Fig. 5B). This was of particular importance for
our study because IL-6 is a key cytokine contributing to CRC
pathogenesis in humans and mice.7,8,27
In line with previous studies,10,20 we found that the IL-33/
ST2 pathway accelerated acute colitis that preceded tumor
development in the AOM-DSS model (Fig. S8). Therefore, it is
Figure 3. IL-33 and St2 expression are induced in CRC in mice. (A) IHC for IL-33 of healthy and tumor WT intestinal tissue. Scale bars: overview: 200 mm; inlay 25 mm. (B)
Increased St2 transcript levels in WT tumor vs. adjacent tumor-free tissue. Data represent means § SEM; n D 9 samples per group; n.d., non-detected. Statistical analysis
was performed using paired t test.
Figure 4. IL-33/ST2 signaling on both the radio-resistant and radio-sensitive com-
partment supports CRC development. (A) Number of tumors and (B) tumor load
was analyzed in the indicated sets of chimeric mice. Data are means § SEM and
representative of one experiment; n D 710 samples per group. Statistical analy-
ses were performed using one-way ANOVA with Bonferroni post-test.
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conceivable that the IL-33/ST2-dependent inﬂammation of the
intestinal epithelium enhances the formation of CRC. However,
enhanced colitis was also found if only the radio-resistant com-
partment was ST2-competent (Fig. S8C), yet these chimeras
were protected from tumorigenesis later on (see Fig. 4). This
suggests that IL-33 contributes to CRC beyond the promotion
of early inﬂammation, by an additional effect on stromal cells.
In the following, we studied IL-33-driven inﬂammatory
changes enhancing CRC. Results from BM chimeras indicated
that the IL-33/ST2 pathway is engaged on the radio-sensitive
compartment to drive tumorigenesis. To assess whether activa-
tion of the IL-33/ST2 pathway on intestinal hematopoietic cells
may contribute to the observed induction of IL-6, we isolated
intestinal leukocytes from DSS-treated mice, stimulated them
ex vivo with IL-33, and measured Il6 transcription. We found
that ﬂow cytometry-sorted CD45C hematopoietic cells from
the lamina propria upregulated Il6 expression upon IL-33 stim-
ulation. An IL-33-dependent increase of Il6 transcript levels
was also detected in immune cells from colon-draining lymph
nodes (Fig. 5C). Therefore, we conclude that IL-33 signaling
elicits IL-6 from intestinal immune cells.
As for IL-33, stronger IL-6 immunoreactivity was observed
in adenomas and low-grade tumors of patients than in healthy
intestine or higher-grade CRCs. This IL-6 staining colocalized
with CD11c-positive cells (Fig. S9, Fig. 5D), indicating the pos-
sible presence of CD11cC dendritic cells that produce IL-6 in
early-stage cancer lesions. Additionally, recombinant IL-6 pro-
moted a dose-dependent phosphorylation of the oncogenic
transcription factor STAT3 in HT-29 and Caco-2 cells (Fig.
S10A and B). This activation is an important step regulating
the proliferation and survival of IECs in vivo.27
Collectively, our ﬁndings suggest that IL-33/ST2 signaling
on radio-resistant cells compromises the intestinal barrier dur-
ing intestinal inﬂammation. This facilitates the translocation of
microbial products to the circulation, which correlates with ele-
vated systemic IL-6 levels. In addition, activation of the
IL-33/ST2 pathway in hematopoietic cells of the intestine leads
to local induction of IL-6. Since IL-6 has the potential to acti-
vate intestinal epithelial cells, we propose that IL-33/ST2 signal-
ing may contribute to colorectal tumorigenesis in part through
IL-6.
Discussion
Progression of CRC is dependent on proliferative and survival
signals from the tumor environment, including immune
cells.4,31 Cytokines, in particular, affect CRC development by
their effect on angiogenesis and cancer cell survival.31 Both its
preferential expression in epithelial barriers and its functional
involvement in intestinal diseases suggested a role for IL-33 in
CRC.
Here, we present evidence that both IL-33 and ST2 proteins
are expressed in colonic tumors in humans, with a preference
in lower grade and stage tumors. We also show that IL-33/ST2
signaling critically contributes to intestinal tumorigenesis in
mice, possibly by inducing the pro-tumorigenic cytokine IL-6
Figure 5. Engagement of the IL-33/ST2 signaling compromises the integrity of the intestinal barrier and stimulates the production of pro-tumorigenic IL-6. Indicated
groups of BM chimeric mice were challenged with DSS and (A) LPS and (B) IL-6 were measured in the serum; n D 59 samples. (C) IL-33 stimulated Il6 expression in lam-
ina propria (LP) and caudal lymph node (CLN) immune cells from DSS-treated WT mice. For LP, cells were pooled from 5 donors and analyzed. Three independent experi-
ments were performed, each represented by a dot. For CLN, cells from four individual mice were analyzed. (D) Serial sections of low-grade human colonic
adenocarcinomas were stained for IL-6 or CD11c. Scale bars: representative overview: 100 mm; inlay 25 mm. Data are means § SEM and show one representative from
two independent experiments. Statistical analyses were performed using Student t test (A, B) and paired Student t test (C).
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(Fig. 6). IL-33 has a dual function, both as an inhibitor of tran-
scription when residing in the nucleus,32 or as a pro-inﬂamma-
tory cytokine upon release.12 Through analysis of St2¡/¡ mice,
we focused on the latter, extracellular role of IL-33.
A functional contribution of the IL-33/ST2 pathway to car-
cinogenesis has so far only been analyzed for few types of solid
tumors, such as head-and-neck squamous cell carcinoma.33
Elevated serum IL-33 was suggested as a negative prognostic
biomarker for lung34 and gastric cancer.35 Our ﬁndings reveal
that IL-33 and ST2 are expressed to a lower extent in advanced
tumors compared to early tumors, yet this difference is not
absolute. Further, our data indicates that IL-33 and ST2 expres-
sion have no prognostic value in CRC. Such cancer type-spe-
ciﬁc differences might be linked to their particular micro-
environments. Indeed, intestinal tumors are directly exposed to
the gut microbiota because tumor development compromises
the intestinal epithelial barrier, as evidenced by the presence of
bacterial 16S rRNA in early human adenomas.30 IL-33 may get
induced in the mucosa as a reaction to bacterial-derived prod-
ucts,13 its release may weaken the intestinal mucosa even more,
and instigate a tissue-destructive feed-forward loop (Fig. 6). In
addition, some IL-33-dependent cytokines like IL-6 may not
only contribute to antibacterial defense but promote tumor
development at the same time.
Our results show that IL-33 and ST2 are expressed predomi-
nantly in low-grade tumors, possibly as an ampliﬁer of the low-
level inﬂammation within tumors.20,30 The reduced expression
of IL-33 and ST2 in poorly differentiated human adenocarcino-
mas may also support the notion that expression of these pro-
teins may be restricted to cells in the diseased intestinal mucosa
that have preserved some epithelial characteristics. However,
the IL-33/ST2 axis may possibly also play a role in higher-grade
and more advanced-stage tumors, as there were for instance
one third of CRCs with higher UICC stage showing ST2 expres-
sion versus two thirds not showing ST2 expression.
Our data suggests that activation of the IL-33/ST2 pathway
may contribute to tumorigenesis by stimulating or amplifying
inﬂammation in early stages of the AOM/DSS model. Consistent
with this interpretation, both transcript and protein levels of Il33
have been reported to be transiently upregulated in the colon of
DSS-treated mice at the peak of acute colitis, and after removal of
DSS to rapidly decline almost to background levels.10,20 This may
explain the unchanged IL-33 expression levels on day 20, i.e. ten
days after the ﬁrst cycle of DSS in our AOM/DSS protocol. More
sustained colonic IL-33 expression is observed as tumors become
established in this model. However, this later increase of IL-33
might be less important for inﬂammatory aspects of tumorigene-
sis, because in established tumors of the AOM/DSS model we
could not detect ST2-dependent selective up- or downregulation
of several inﬂammatory transcripts.
Our data also suggests that the inﬂammatory inﬁltrate
within tumors is distinct in different stages of CRC
Figure 6. Model for the role of the IL-33/ST2 pathway in CRC. (A) Stress/damage drives the production and release of IL-33 which binds to its receptor ST2 on immune
effector cells and (B) drives the production of pro-tumorigenic factors, including IL-6. (1) IL-33 also binds to ST2 on IECs, (2) which decreases the tightness of the intestinal
barrier and (3) promotes the translocation of intestinal bacteria or bacterial products via the blood stream. Bacteria-derived molecules such as LPS enter otherwise sterile
compartments and engage innate immune receptors such as Toll-like receptors (TLRs) (4) to trigger the production of pro-inﬂammatory cytokines, including IL-6. It is not
clear whether ST2C immune cells also express TLRs. (5/C) IL-6 acts on IECs to promote tumor development via the phosphorylation of the oncogenic transcription factor
STAT3.
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development, and further investigations will help identify these
stage-speciﬁc molecular crosstalks of tumors and the tumor
microenvironment.
Our results indicate that BM chimeric mice with ST2 expres-
sion restricted to their radio-resistant stromal cells develop fewer
and smaller tumors than WT-to-WT chimeras, although they
show strong clinical symptoms during acute DSS treatment.
This suggests a stromal cell-intrinsic tumorigenic mechanism
that depends on ST2 and that is distinct from ST2-mediated reg-
ulation of intestinal permeability. The nature of this mechanism
is yet to be characterized.
A recent study by Liu et al. reported that IL-33 expression in
a xenotransplant model of human SW620 CRC cells into nude
mice promoted lung metastasis.36 However, we did not ﬁnd
any signiﬁcant association between IL-33/ST2 expression in
primary tumors and metastasis to lymph nodes in CRC
patients. Furthermore, combined positive expression of ST2
and IL-33 negatively correlated with venous invasion in our
cohort. Hence, our investigation focused on CRC tumorigenesis
rather than on metastasis, in line with a recent report describ-
ing elevated IL33 and ST2 transcript levels in colorectal
adenomas.37
Our ﬁndings indicate that engagement of IL33/ST2 signaling
stimulates the production of tumor-promoting IL-6, at least
during the inﬂammatory phase of the AOM/DSS model. It is
likely that other pro-tumorigenic cytokines besides IL-6 are
secreted after ST2 activation and it remains to be investigated
whether IL-33/ST2 engagement in colorectal tumors induces
additional pro-tumorigenic mediators.
Besides stimulating the production of pro-tumorigenic IL-6,
activation of the IL-33/ST2 axis may also lead to an accumula-
tion of myeloid-derived suppressor cells38,39 or promote regula-
tory T cell (Treg) function
40 to negatively control the antitumor
response. Indeed, high frequency of tumor-inﬁltrating FOXP3C
cells has been associated with early pT-stage tumors in a large
cohort of mismatch-repair proﬁcient CRC patients.41 In light
of our data indicating overexpression of ST2/IL-33 in pT1-2
tumors, it may be relevant to address whether Tregs exert an IL-
33/ST2 signaling-dependent suppressive function in CRC
lesions.
Our TMA-based approach allowed large scale analysis of
CRC cases; however the size of the tissue cores limited this
analysis to the study of IL-33/ST2 expression in IECs. There-
fore, this technique did not allow us to examine how expression
of IL-33 or ST2 by other cell types is associated with CRC stages
and grades. Our functional data from mouse experiments
shows that immune cells in the tumor environment respond to
IL-33 by secreting pro-tumorigenic IL-6. Further studies are
needed to dissect the role of non-epithelial stromal cells such as
myoﬁbroblasts for IL-33/ST2-dependent CRC.
In conclusion, our study demonstrates that activation of the
IL-33/ST2 pathway on epithelial and immune cells critically
modulates colon tumorigenesis. Since IL-33 and ST2 expres-
sion patterns are temporally and spatially restricted during
CRC progression in patients, it is conceivable that this pathway
preferentially drives early-stage events of colon carcinogenesis.
Therefore, a therapeutic inhibition of the IL-33/ST2 axis might
curtail CRC progression, particularly when applied at an early
stage of tumor development.
Methods
Patient selection
Formalin-ﬁxed parafﬁn-embedded (FFPE) CRC resections of
713 patients diagnosed throughout a 19-year period
(19932011) at two different institutions in Switzerland (Insti-
tute of Surgical Pathology Zurich and Institute of Pathology
Liestal) were examined. The Zurich CRC cohort was described
before42 and consisted of 253 patients. The Liestal CRC cohort
consisted of 471 patients. The study was approved by the Can-
tonal Ethics Committees of Zurich and Basel. Clinicopathologi-
cal patient characteristics are shown in Table S2. In addition,
the Liestal cohort contained 11 patients with synchronous
CRCs. In these 11 patients, two tumors at different positions in
the colon were diagnosed at the same time point and were both
included in the TMA. CRCs with pre-operative treatment were
excluded from the analysis.
Construction of tissue microarrays and scoring for IL-33
and ST2
All tumors were re-evaluated by at least two board-certiﬁed
pathologists (K.D.M., T.T., G.C., A.W.) according to WHO cri-
teria. Two TMAs of each CRC cohort were constructed as
described previously.43 The Liestal cohort was stained for both
IL-33 and ST2, the Zurich cohort for IL-33. Only nuclear IL-33
immunohistochemical staining in epithelial cells was scored as
positive and endothelial cells served as internal control for IL-
33 positivity. The percentages of IL-33- and ST2-positive
epithelial cells in patient samples were recorded by two board-
certiﬁed pathologists (K.D.M. and G.C.) in a blinded manner.
Immunohistochemistry of human tissue
Immunohistochemistry of TMA sections was performed as
previously described.10 Brieﬂy, sections were pre-incubated on
the BondMax system (Leica) in Bond Epitope Retrieval Solu-
tion 2 (Leica, AR9640) (pH 9.0) for 30 min at 95C, and then
stained either for IL-33 (1:400, goat anti-human IL-33 IgG,
R&D systems, AF3625), or for ST2 (1:400, rabbit anti-human
ST2, Sigma Aldrich, PRS3363). The Bond Polymer Reﬁne Red
Detection kit (Leica, DS9390) was used for detection of both
IL-33 and ST2.
Alternatively, serial full tissue sections of FFPE resection speci-
mens were cut and stained either for CD11c (1:100, clone 5D11,
Leica, PA0554) after pre-treatment in Tris buffer at 95C for
40 min or for IL-6 (1:3000, Abcam, ab9324) after pre-treatment
in Tris buffer at 95C for 20min. Speciﬁc binding of primary anti-
bodies was visualized using a polymer-based visualization system
with horseradish peroxidase as the enzyme (EnvisionC; Dako,
K4006) and 3,30-diaminobenzidine as the chromogen. Slides were
scanned using an Aperio Scanscope (Leica).
Induction and assessment of intestinal tumors in mice
All animal experiments were performed in accordance with
Swiss Federal regulations and were approved by the Cantonal
Veterinary Ofﬁce. C57BL/6J mice were purchased from Jackson
e1062966-8 K. D. MERTZ ET AL.
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Laboratories and subsequently bred in-house. Il1rl1¡/¡ (St2¡/¡)
mice were previously described44 and backcrossed on a C57BL/
6J background.
As a model for CRC induction, we used the AOM (Sigma,
A5486)/DSS (MP Biomedicals, 0216011090) model as previ-
ously described.45 Seven days after injection with AOM, mice
were given 1% DSS in the drinking water for up to 5 d, followed
by 7 d of water. After this, mice received a second injection of
AOM, followed by 2 cycles of 1% DSS and water. Unless other-
wise indicated, mice were sacriﬁced 70 d after the ﬁrst injection
of AOM.
For matching of commensal communities between experi-
mental groups before AOM/DSS treatment, mice were co-
housed for 34 weeks or soiled bedding was exchanged
between cages for a similar duration. Also, soiled bedding was
exchanged at least weekly and for the entire duration of an
experiment.
Macroscopic tumors were counted by two independent
observers. Tumor load was measured as previously described,22
and gene expression level was performed. Tumors were graded
by a board-certiﬁed pathologist (A.L.), in a blinded manner.
Criteria for grading are listed in Supplementary Material and
Methods.
Evaluation of barrier permeability
Animals were given DSS in the drinking water for 5 d followed
by 3 d of water. Serum, lymph nodes, spleen, liver and colon
were taken to analyze barrier integrity. LPS in the serum of ani-
mals was measured using the Pierce LAL Chromogenic Endo-
toxin Quantitation Kit (Thermo Scientiﬁc, 88282) according to
the manufacturer’s protocol. 16S rRNA and IL-6 were mea-
sured through qPCR and ELISA respectively.
Isolation and ex vivo stimulation of immune cells
Mice were treated with DSS and immune cells were harvested
after homogenization of caudal lymph node (CLN) or after
puriﬁcation of CD45C cells by ﬂow cytometry from single-cell
suspensions of the colonic lamina propria. Cells were then
stimulated ex vivo with 100 ng/ml recombinant murine IL-33
(Peprotech, 210-33). Thirty hours later, cells were harvested for
qPCR analysis.
Statistical analysis
In a ﬁrst step, clinicopathological features of both patient
cohorts were evaluated. Since no statistically signiﬁcant differ-
ences in the distribution of relevant prognostic parameters
were identiﬁed, the two cohorts were pooled. Next, a random
subset of 30% of all patients (n D 217) was selected. Receiver
Operating Characteristic (ROC) curve analysis was performed
to identify the optimal immunohistochemical cut-off score for
IL-33 and ST2 best discriminating between patients who are
deceased or censored/alive. The reliability of the cut-off scores
was determined by 500 bootstrapped resamples of the data.
The ﬁnal cut-off score of 5% for IL-33 and 30% for ST2 was
assigned. Next, the two cut-off scores were applied to the entire
cohort of patients and associations with clinicopathological fea-
tures and survival time was analyzed. Categorical variables
were analyzed using the Chi-Square or Fisher’s Exact test, while
continuous variables with Wilcoxon’s Rank Sum Test.
KaplanMeier curves and log-rank test for univariate survival
analysis was performed and Cox regression models, after veriﬁ-
cation of the proportional hazards model were also analyzed.
Missing data was considered to be missing at random. Analyses
were carried out using SAS V9.4 (The SAS Institute).
For in vivo and in vitro studies, statistical evaluations were
performed using GraphPad Prism v.5.04 for Windows (Graph-
Pad Software). Only statistically signiﬁcant differences are indi-
cated in the ﬁgures.
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